Repeated Neurocognitive Measurements in Depressed Patients

This interventional trial (n=20) aims to conduct repeated neurocognitive measurements in depressed patients, treated with ketamine, specifically those with unipolar depression.

Led by Jay Fournier from Ohio State University, the study plans to commence in May 2024. The primary goal is to track the functioning of potential neurobiological targets for depression over time and examine their relationship with real-world functioning. Additionally, a subset of participants will receive a single dose of intravenous ketamine to determine its effect on these targets.

Participants must be between 18 and 60 years old and have a Hamilton Depression Rating Scale (Ham-D) score of at least 14. Exclusion criteria include conditions such as bipolar disorder, substance use disorder, and acute suicidality.

The primary outcome measure will be fMRI resting-state connectivity, assessed 24 hours post-intervention. Secondary outcome measures include depression ratings using the Montgomery-Asberg Depression Rating Scale and the Hamilton Depression Rating Scale at various time points post-intervention. The study is expected to conclude in December 2025.

Topic Depression
Compound Ketamine
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 May 2024
End date 31 December 2025
Phase Phase I Phase II
Design Open
Type Interventional
Participants 20
Sex All
Age 18- 60
Therapy No

Trial Details

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

NCT Number NCT05991232

Sponsors & Collaborators

Ohio State University
The Center for Psychedelic Drug Research & Education (CPDRE) at the College of Social Work at Ohio State University aims to explore and advance the research about psychedelic drugs and their effects, and to disseminate the knowledge about psychedelics.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.
?>